Pharmacists and industry: Guidelines for ethical interactions

Pharmacotherapy

Volumn 28, Issue 3, 2008, Pages 410-420

  Hatton, Randy C ^a   Chavez, Mary L ^a   Jackson, Eric ^a   Maurey, Julie ^a   Barriere, Steven L ^a   Couchenour, Rachel ^a   Evens, Ronald P ^a   Gunning, Karen ^a   Hume, Anne L ^a   Hutchison, Lisa C ^a   Matzke, Gary R ^a   Noviasky, John A ^a   Rospond, Raylene M ^a   Kelloway, Judy Shepard ^a   Stevenson, James G ^a   Vanderveen, R Pete ^a   Verme Gibboney, Catherine N ^a   Walters, Debra ^a  

^a NONE   (United States)

Author keywords

ACCP; American College of Clinical Pharmacy; Conflict of interest; Disclosure; Ethical interactions; Gifts; Industry interactions; Professional relationships

Indexed keywords

CLINICAL PRACTICE; CONTINUING EDUCATION; DECISION MAKING; DRUG INDUSTRY; HEALTH CARE PERSONNEL; LAW; MEDICAL ETHICS; MEDICAL RESEARCH; PHARMACIST; PRACTICE GUIDELINE; PUBLICATION; REVIEW;

CONFIDENTIALITY; CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; EDUCATION, PHARMACY; ETHICS, PHARMACY; HUMANS; PERIODICALS AS TOPIC; PHARMACISTS; SOCIETIES, PHARMACEUTICAL;

EID: 40149099001     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.3.410     Document Type: Review

References (64)

1. American College of Clinical Pharmacy. Pharmacists and the pharmaceutical industry: guidelines for ethical interactions. Pharmacotherapy 1993;13:531-3.
2. Pharmaceutical Research and Manufacturers of America. Code on interactions with healthcare professional. Available from http://www.phrma.org/ code_on_interactions_with_healthcare_professionals/. Accessed March 7, 2007.
3. U.S. Department of Health and Human Services Office of Inspector General. OIG compliance program guidance for pharmaceutical manufactures. Federal Register 2003;68(86):23731-43.
4. Accreditation Council for Continuing Medical Education. 2004 Updated standards for commercial support with background, rationale and answers to questions about compliance. Chicago, IL: Accreditation Council for Continuing Medical Education, 2004.
5. Accreditation Council for Pharmacy Education. Criterion 17. Non-commercialism. Adopted October 2006. Available from http://www.acpe- accredit.org/pdf/CE_NEW_CommercialismStandard17%20-%202006.pdf. Accessed March 9, 2007.
6. American Pharmaceutical Association. Code of ethics for pharmacists. Adopted October 27, 1994. Available from http://www.aphanet.org. Accessed March 7, 2007.
7. American Society of Health-Systems Pharmacists. Code of ethics for pharmacists. Am J Health-Syst Pharm 1995;52:2131.
8. Benner J, Breadsley R. White paper on pharmacy student professionalism. J Am Pharm Assoc 2000;40:96-102.
9. American Pharmacists Association. Principles of practice for pharmaceutical care. Available from http://www.aphanet.org. Accessed March 7, 2007.
10. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-80.
11. Turton FE, Syndor L. Physician-industry relations [letter]. Ann Intern Med 2007;146:469.
12. Komesaroff P, Kerridge IH. Ethical issues concerning the relationships between medical practitioners and the pharmaceutical industry. Med J Aust 2002;176:118-21.
13. Dana J, Lowenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003;290:252-5.
14. Katz D, Caplan AL, Merz JP. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth 2003;3:39-46.
15. Blumenthal D. Doctors and drug companies. N Engl J Med 2004;351:1885-90.
16. American College of Obstetricians and Gynecologists. Committee on ethics. ACOG committee opinion. Guidelines for relationships with industry. No. 259, October 2001. Obstet Gynecol 2001;98:703-6.
17. Tsai AC. Policies to regulate gifts to physicians from industry. JAMA 2003;290:1776.
18. Chlong W. Industry-to-physician marketing and the cost of prescription drugs. Am J Bioeth 2003;3:W28-9.
19. Abbasi K, Smith R. No more free lunches [editorial]. BMJ 2003;326:1155-6.
20. Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians. Arch Intern Med 2003;163:2213-18.
21. Panush RS. Why I no longer accept pens (or other "gifts") from industry (and why you shouldn't either). J Rheumatol 2004;31:1478-82.
22. Alpert JS. Doctors and the drug industry: how can we handle potential conflicts [editorial]? Am J Med 2005;118:99-100.
23. Gosfield AG. The hidden costs of free lunches: fraud and abuse in physician-pharmaceutical arrangements. J Med Pract Manage 2005;20:253-8.
24. Marco CA, Moskop JC, Solomon RC, Geiderman JM, Larkin GL. Gifts to physicians from the pharmaceutical industry: an ethical analysis. Ann Emerg Med 2006;48:513-21.
25. Scott IA. On the need for probity when physicians interact with industry. Intern Med J 2006;36:265-9.
26. Kassirer JP. When physician-industry interactions go awry. J Pediatr 2006; 49(1 suppl):S43-6.
27. Minnigan H, Chisholm CD. Conflict of interest in the physician interface with the biomedical industry. Emerg Med Clin North Am 2006;24:671-85.
28. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006;295:429-33.
29. Standridge JB. Of doctor conventions and drug companies. Fam Med 2006;38:518-20.
30. Day L. Industry gifts to healthcare providers: are the concerns serious? Am J Crit Care 2006;15:510-13.
31. Schwartz B. Receiving gifts: a conflict of interest discussion. J Can Dent Assoc 2005;71:561-2.
32. Haines ST, Dumo P. Relationship between the pharmaceutical industry and pharmacy practitioners: undue influence? Am J Health-Syst Pharm 2002;59:1871-4.
33. Banks D. Pharmacists, pharmaceutical manufacturers, and conflicts of interest. Am J Health-Syst Pharm 2005;62:1827-32.
34. Paris JJ. Large or small, a gift is a gift is a gift. Am J Bioeth 2003;3:W30.
35. Wager E. How to dance with porcupines: rules and guidelines on doctors' relations with drug companies. BMJ 2003;326: 1196-8.
36. Coyle SL. Physician-industry relations. Part I. Individual physicians. Ann Intern Med 2002;136:396-402.
37. Trachtman H. The death of common sense. Am J Bioeth 2003;3:W31-2.
38. Chren MM. Interactions between physicians and drug company representatives. Am J Med 1999;107:182-3.
39. Chimonas S, Rothman DJ. New federal guidelines of physician-pharmaceutical industry relations: the politics of policy formation. Health Affairs 2005;24:949-60.
40. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experience with disclosure laws in Vermont and Minnesota. JAMA 2007;297:1216-23.
41. Brennan TA, Mello MM. Sunshine laws and the pharmaceutical industry. JAMA 2007;297:1255-7.
42. Thompson DF. Understanding financial conflicts of interest. N Engl J Med 1993;329:573-6.
43. Dickens BM, Cook RJ. Conflict of interest: legal and ethical aspects. Int J Gynaecol Obstet 2006;92:192-7.
44. American Society of Hospital Pharmacists. ASHP statement on the pharmacy and therapeutics committee. Am J Hosp Pharm 1992;49:2008-9.
45. American Society of Health-Systems Pharmacists Coalition Working Group. Principles of a sound drug formulary system. Available from http://www.ashp.org/bestpractices/formulary-mgmt/ Formulary%20Management%20Endorsed.pdf. Accessed July 11, 2003.
46. Katz S, Dudley EW, Veatch RM. Potential conflict of interest of a pharmacy and therapeutics committee member. Am J Hosp Pharm 1989;46:2047-51.
47. Zilz DA. Interdependence in pharmacy: risks, rewards, and responsibilities. Am J Hosp Pharm 1990;47:1759-65.
48. Frye CB. Disclosing conflicts of interest involving clinicians who prepare therapeutic guidelines. Am J Health-Syst Pharm 2005;62:361-2.
49. Anonymous. Clinical practice guidelines and conflict of interest [editorial]. Can Med Assoc J 2005;173:1297.
50. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612-17.
51. U.S. Department of Health and Human Services. Protection of human subjects. Code of federal regulations, title 21, vol 1, pt 50. Washington, DC: U.S. Government Printing Office, April 1, 2002:285-96.
52. U.S. Department of Health and Human Services. Institutional review boards. Code of federal regulations, title 21, vol 1, pt 56. Washington, DC: U.S. Government Printing Office, April 1, 2002:299-308.
53. Nabel EG. Conflict of interest or conflict of priorities [editorial]? N EnglJ Med 2006;355:2365-7.
54. American College of Clinical Pharmacy. ACCP white paper: ethical issues related to clinical pharmacy research. Pharmacotherapy 1993;13:523-30.
55. American College of Clinical Pharmacy. ACCP white paper: ethical issues related to clinical, translational, and health systems research. Pharmacotherapy, in press.
56. U.S. Food and Drug Administration, Department of Health and Human Services. Objectivity in research; investigatory financial disclosure policy; final rule and notice. Federal Register 1995;60(132):35809-19.
57. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability [editorial]. Ann Intern Med 2001;135:463-6.
58. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. February 2006. Available from www.icmje.org. Accessed March 7, 2007.
59. Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Curr Med Res Opin 2003;19: 149-54.
60. Hasegawa GR. Full disclosure [editorial]. Am J Health-Syst Pharm 2002;59:1835.
61. Accreditation Council for Pharmacy Education. Definition of continuing education for the profession of pharmacy, released January 2007. Available from http://www.acpe-accredit.org/pdf/ CE_Definition_Pharmacy_Final_1006-2007.pdf. Accessed March 9, 2007.
62. Hammer DP, Berger BA, Beardsley RS, Easton MR. Student professionalism. Am J Pharm Educ 2003;67(3):article 96.
63. U.S. Department of Health and Human Services. Office for civil rights - HIPAA. Available from http://aspe.hhs.gov/admnsimp/pl104191.htm. Accessed March 24, 2007.
64. Steinbrook R. For sale: physicians' prescribing data. N Engl J Med 2006;354:2745-7.